Azilect (rasagiline)
- Region
- 🇪🇺 EU
- Active substance
- rasagiline
- Company
- Teva B.V.
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- CHMP opinion
- Mon 14 Aug 2023
- EU approval
- Mon 21 Feb 2005
- Application
- EMEA/H/C/000574
- ATC
- N04BD02
- Official record
- www.ema.europa.eu
Indication
Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rasagiline Viatris (previously Rasagiline Mylan) Authorised · Viatris Limited
- 🇪🇺 Rasagiline ratiopharm Authorised · Teva B.V.
Follow Azilect
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.